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ABSTRACT
The aims of this study were to investigate the potential of microbial cultures of
dairy significance to produce conjugated fatty acids exhibiting beneficial anti-
microbial and anti-carcinogenic activities. Supplementation of reconstituted
skimmed milk with food grade yeast extract, sodium acetate and inulin enhanced
production of the health promoting conjugated linoleic acid (CLA) by
bifidobacteria. Three novel microbially-produced conjugated fatty acids were
isolated and identified using RP-HPLC and GLC-MS. These conjugated fatty acids
exhibited potent anti-carcinogenic activity associated with increased cellular lipid
oxidation and altered expression of Bcl-2 in the SW480 human colon cancer cell
line. These novel conjugated fatty acids also displayed potent inhibitory activity
against methicillin resistant Staphylococcus aureus (MRSA). It was observed that
the pattern of inhibition displayed by the conjugated fatty acids differed
substantially from that of their parent unsaturated fatty acids. Furthermore, it was
observed that the conjugated fatty acids remained active in the presence of known
inactivators of the inhibitory activity of unsaturated fatty acid such as blood serum
and -tocopherol. Bovine nutrition intervention trials showed that dietary
supplementation with -3 PUFA elevated concentrations of -3 PUFA and the
concentration of CLA and its precursor vaccenic acid. Furthermore, such a diet
could be used to enhance the-3/-6 PUFA and PUFA/saturated fatty acid profiles
of plasma, meat and liver from beef heifers. In conclusion, the results demonstrate
that 1) members of the enteric microbiota possess the ability to biosynthesise novel
conjugated fatty acids with positive benefits for human health and 2) dietary -3
PUFA supplementation in cows leads to changes in fatty acid profiles of tissues
which positively impact on the nutritive quality of bovine meat.
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